Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arkadiusz Dudek

Medical Oncology Rochester, MN Medical Doctor

NPI 1538197181 CMS profile 160756

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$8,027

16 records reported · program years 2019–2025

Research payments

$6,400

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,744,718 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Arkadiusz Dudek of Rochester, MN is reported in the CMS Open Payments database as having received $8,027 across 16 general payments and $6,400 in research payments paid to them. Separately, studies naming them as principal investigator received $4,744,718 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,866 6
2022 General $107 2
2022 Research $3,200 1
2021 General $1,261 2
2021 Research $3,200 1
2020 General $732 5
2019 General $3,060 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arkadiusz Dudek
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Arkadiusz Dudek were reported at $2,866. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Arkadiusz Dudek Medical Oncology median Middle half National median
2019 $3,060 $968 $140–$6,658 $163
2020 $732 $747 $102–$5,891 $114
2021 $1,261 $430 $50–$4,098 $132
2022 $107 $812 $127–$4,907 $149
2023 $0 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $2,866 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $3,100 2 payments
  2. Iovance Biotherapeutics, Inc. $2,806 5 payments
  3. Seattle Genetics, Inc. $1,250 1 payment
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $650 1 payment
  5. Takeda Pharmaceuticals U.S.A., Inc. $85 1 payment
  6. E.R. Squibb & Sons, L.L.C. $64 4 payments
  7. AstraZeneca Pharmaceuticals LP $60 1 payment
  8. Deciphera Pharmaceuticals Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $4,960 3 payments
  2. Honoraria $2,400 1 payment
  3. Food and Beverage $290 5 payments
  4. Travel and Lodging $261 1 payment
  5. Education $116 6 payments
Products named General payments · program years 2019–2025
  1. Bavencio $3,060 1 payment
  2. Amtagvi $2,806 5 payments
  3. PADCEV $1,250 1 payment
  4. GILOTRIF $650 1 payment
  5. OPDIVO $23 2 payments
  6. Revlimid $19 1 payment
  7. QINLOCK $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $6,400 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

102

Median for Medical Oncology: 414

Drug cost

$885

Median for Medical Oncology: $849,427

Branded share of claims

10.8%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Budesonide Ec Budesonide Brand 11 $223
Prochlorperazine Maleate Generic 20 $202
Ondansetron Hcl Generic 20 $190
Levothyroxine Sodium Generic 21 $136
Prednisone Generic 30 $135

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$1,536,666

Of which drugs: $1,464,788

Medicare patients

351

Average age 72

Services billed

66,547

166 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Cancer 44%
Arthritis 34%
Chronic kidney disease 31%
Diabetes 25%
Ischemic heart disease 23%
Atrial fibrillation 21%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 33 9,300 $406,457
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 30 5,590 $218,061
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg Q5115 Office 11 810 $20,795
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 11 55 $7,691
Injection, bortezomib (velcade), 0.1 mg J9041 Office 23 1,305 $1,845
Injection, fosaprepitant, 1 mg J1453 Office 32 5,700 $632
Injection, palonosetron hcl, 25 mcg J2469 Office 64 750 $535
Injection, fluorouracil, 500 mg J9190 Office 18 206 $477
Injection, carboplatin, 50 mg J9045 Office 20 147 $408
Injection, paclitaxel, 1 mg J9267 Office 24 4,644 $378

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record